SEP 30, 2015 07:30 AM PDT

How do I choose? Androgen Biosynthesis Inhibitor, Androgen Receptor Antagonist, or both for treatment of mCRPC?

C.E. CREDITS: CE
Speakers
  • Director of Research, CPI & Attending Urologist, The Urology Center of Colorado
    Biography
      Dr. Karsh has practiced Urology in Denver since 1984 and was board Certified in 1986, completing the most recent recertification in 2013. He graduated from the Chicago Medical School and completed his General Surgical training at The University of Colorado Health Sciences Center under Dr. Thomas Starzl. He completed his Urology residency at Brigham and Women's Hospital/Harvard Medical School under Dr. Ruben Gittes.

      Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist and Director of Research. He is a principal investigator with an experience of more than 160 clinical trials. He is a Certified Principal Investigator, certified by the Association of Clinical Research Professionals (ACRP.) Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for "Urologists in Cancer Care" and "Bladder Cancer." He is an active member of the AUA, ASCO, SWOG as well as the SUO. He serves on the bladder cancer subcommittee for the SUO Clinical Trials Consortium and is a member of the Denver Academy of Surgeons.

      Dr. Karsh serves as an advisor and consultant to the pharmaceutical industry, participating in drug development and research protocols. He educates physicians across the country about newly approved therapies.

      In his spare time, Dr. Karsh is an avid road bicycler and skier.

    Abstract:

    The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prior 3 decades. The purpose of this program is to outline the therapies that have been approved since 2010 and focus on the oral therapies, in particular Abiraterone and Enzalutamide. A practical discussion will include the mechanisms of action, the clinical trials resulting in approval by the FDA, the indications for their use and potential side effects. I will briefly discuss resistance mechanisms including ARV 7 splice variant and will discuss combination therapies in development. I will conclude the program with strategies for sequencing the new landscape of therapeutic options. The program will include audience questions and answers.


    Show Resources
    You May Also Like
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    JUN 20, 2018 10:00 AM EDT
    C.E. CREDITS
    JUN 20, 2018 10:00 AM EDT
    DATE: June 20, 2018TIME: 07:00AM PDT, 10:00AM EDTIntroducing GE’s New Lyo-StableTM service. Sepsis is one of the top challenges facing hospitals in terms of clinical outcomes...
    Loading Comments...